QNCX quincetx.com Earnings growth forecast for next year

Corporate emblem and logo of Quince (QNCX)

This chart on GURU.Markets shows moderate EPS growth prospects for the next fiscal year for Quince Therapeutics (QNCX), with the value holding at 0.00. This trend reflects the implementation of the AOC platform for treating rare metabolic pathologies. Stability is provided by the protection of drug delivery IT technologies and strict FDA control, as well as a patent shield in the field of targeted bone tissue therapy.

Quince (QNCX): Expected net earnings per share growth next year from 04/28/2023 to 10/12/2026

QNCX (Quince): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
Initial company analysis:QNCX, Quince Therapeutics Inc
Finished products of Quince Therapeutics Inc

Long-term investing requires strict volatility control and an analysis of fundamental market expectations. For Quince Therapeutics (QNCX), this directly depends on the efficiency of temperature control during the transport of biomaterials, which impacts the success of clinical deliveries. The current trajectory of next year's EPS forecasts reflects the market consensus on profit dynamics, stripped of speculation, allowing for an assessment of the business's future profitability.

Analysis of competing companies

ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|89bio Pharma (ETNB) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year agios.com (AGIO)|Expected earnings per share growth for next year structuretx.com GPCR|Net earnings per share growth forecast for next year MiMedx Group Inc MDXG|Expected earnings per share trend next year RZLT|lexpharma.com - Earnings growth forecast for next year|MBX (MBX Biosciences Inc) - Projected earnings per share growth rate for next year|ALT: Earnings growth forecast for next year|Aardvark Therapeutics Inc - Expected earnings per share trend next year|SGMT (Sagimet Biosciences, Inc.) - Earnings growth forecast for next year|Earnings growth forecast for next year BioAge|Earnings growth forecast for next year BMEA|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year